Ovarian cancer is a therapeutic challenge. Despite the existing treatments (chemotherapy, PARP inhibitors and VEGF inhibitors), most patients develop resistance and therefore the survival rates are extremely low. The global ovarian cancer patient market represents about 300 thousand patients per year. This market is also expected to grow by nearly 40 percent by 2040. The disease is considered an orphan drug and therefore the regulatory pathway at the FDA is fast and with leniencies in development.

DIO3 is expressed at a high level in ovarian cancer high grade serous (HGSOC), an aggressive disease with extremely high mortality rates. The technology involved a series of small molecules, the first of their kind for specific inhibition of DIO3. 

 Finally, the DIO3 enzyme is expressed in other aggressive tumors, including breast and lung cancer, and therefore the drugs have an even greater market potential.

Dio Tree

Org chart

Teams

Offices